Pitavastatin better for dyslipidaemia control in T2DM patients with LEAD
Both pitavastatin and atorvastatin effectively reduce femoral total plaque area in type 2 diabetes mellitus (T2DM) patients with lower extremity atherosclerotic disease (LEAD), a new study has found. On the other hand, pitavastatin leads to better levels of high-density lipoprotein cholesterol.